NVO — The baseline matters as much as the growth rate

Novo Nordisk's profit grew or fell in the same quarter, depending on which measure you read. The difference tells investors what to investigate.

In its November 4 release, $NVO reported third-quarter sales of about 79.2 billion Danish kroner, up 4% at constant exchange rates. That basis removes currency movements from the growth comparison.

Adjusted operating profit rose 27% on that basis. Reported operating profit fell 9%.

The company identified 8.7 billion kroner of noncash asset write-downs in the quarter, related to a drug program and manufacturing facilities. Its adjusted figure excludes those charges. A write-down reduces the recorded value of assets and lowers reported profit, without an equivalent cash payment that quarter.

That explains the split between the two profit measures. It does not make the lost asset value unimportant.

The growth comparison needs another check. Management said the adjusted profit increase also benefited from comparison with 9 billion kroner of transformation costs recognized a year earlier. A weaker starting year can make subsequent growth look especially strong.

The useful research task has three parts: examine sales growth, understand this year's write-downs, and account for last year's unusual costs.

The results contain evidence of progress, but the 27% alone cannot establish a sustainable profit-growth rate. Watch the next product-sales disclosure and profit reconciliation. The recovery case strengthens if demand improves without depending on unusual charges dropping out of the comparison.

Source: https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=919765